In Situ Caries of Fluoride Toothpastes

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00708123
First received: July 1, 2008
Last updated: NA
Last verified: July 2008
History: No changes posted

July 1, 2008
July 1, 2008
November 2007
 
To use an in situ caries model to compare the retention phase of fluoride delivery from two test sodium fluoride toothpastes to a monofluorophosphate/ sodium fluoride toothpaste with respect to enamel remineralization potential.
Same as current
No Changes Posted
Comparisons between treatments with respect to enamel remineralization potential. To compare the retention phase of fluoride delivery of all the study toothpastes to placebo and to each other with respect to enamel fluoride uptake.
Same as current
 
 
 
In Situ Caries of Fluoride Toothpastes
Comparison of the Clinical Efficacy From the Retention Phase of Fluoride Delivery of Fluoride Toothpastes Using an in Situ Caries Model

This study is to evaluate the effect of fluoride dentifrices on enamel with artificial caries lesions in an in situ model.

 
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Healthy Volunteers
  • Partial Denture Wearers
Drug: Fluoride
 
 

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
57
 
 

Inclusion Criteria

  1. Consent Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
  2. Age Aged between 18 and 78 years.
  3. Compliance Understands and is willing, able and likely to comply with all study procedures and restrictions.
  4. General Health Good general health with (in the opinion of the investigator) no clinically significant and/or relevant abnormalities of medical history or oral examination that could interfere with subject safety during the study period.
  5. Diagnosis Oral

    1. Currently living in the Indianapolis area which is a fluoridated community (1 ppm F).
    2. Currently wearing a removable mandibular partial denture with sufficient room in the posterior buccal flange area to accommodate two enamel specimens (required dimensions 12 x 7 millimeters (mm)).
    3. Willing and capable of wearing their removable partial dentures 24 hours per day during each two week treatment period.
    4. All restorations in a good state of repair.
  6. Salivary Flow Have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate = 0.2 ml/minute; gum base stimulated whole saliva flow rate = 0.8 ml/minute).

Exclusion Criteria

  1. Pregnancy Women who are known to be pregnant or who are intending to become pregnant over the duration of the study. No pregnancy test will be required.
  2. Breast-feeding Women who are breast-feeding.
  3. Allergy/Intolerance Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  4. Clinical Study/Experimental Medication Participation in another clinical study or receipt of an investigational drug within 30 days of the first treatment visit, with the exception of study T3157495 where the wash in period prior to treatment is sufficient.
  5. Antibiotics Currently taking antibiotics or have taken antibiotics in the 2 weeks prior to the screening visit.
  6. Fluoride Taking fluoride supplements for medical reasons.
  7. Dental Health Current active caries or periodontal disease that may compromise the study or health of the subjects.
  8. Personnel

    1. A member of the site study staff
    2. An employee of the sponsor
    3. Any employee of any toothpaste manufacturer or their spouse or family member.
Both
18 Years to 78 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00708123
T3157503
 
 
GlaxoSmithKline
 
Study Director: GSK Clinical Trials, DDS GlaxoSmithKline
GlaxoSmithKline
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP